Molecular classification of gastric cancer

Annals of Oncology

Volumn 27, Issue 5, 2016, Pages 763-769

  Chia, N Y ^a   Tan, Patrick ^a,b,c,d  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

gastric cancer; Molecular classification; Subtypes; TCGA

Indexed keywords

APC PROTEIN; AZD 4547; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCITATORY AMINO ACID TRANSPORTER 2; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HERMES ANTIGEN; METHYL CPG BINDING PROTEIN 2; NIMOTUZUMAB; ONARTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIRTUIN 1; SODIUM PHOSPHATE COTRANSPORTER 2B; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; TRASTUZUMAB; UVOMORULIN;

AKT1 GENE; AKT2 GENE; AKT3 GENE; APC GENE; ARHGAP26 GENE; ARID1A GENE; ARID1B GENE; CANCER RESISTANCE; CANCER STAGING; CCND1 GENE; CCNE1 GENE; CD44 GENE; CDH1 GENE; CDK6 GENE; CELL PROLIFERATION; CHD3 GENE; CHD4 GENE; CHROMOSOMAL INSTABILITY; CLDN18 GENE; COHORT ANALYSIS; CTNNA1 GENE; CTNNB1 GENE; DRUG SENSITIVITY; E2F1 GENE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; ERBB2 GENE; FAT4 GENE; FUSION GENE; GATA4 GENE; GATA6 GENE; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENOMIC INSTABILITY; HER2 GENE; HETEROZYGOSITY LOSS; HNF4A GENE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KLF5 GENE; MBD2 GENE; MISMATCH REPAIR; MLL2 GENE; MLL3 GENE; MOLECULAR CLASSIFICATION; MOLECULAR DYNAMICS; NME1 GENE; ONCOGENE K RAS; OVERALL SURVIVAL; PATHOGENESIS; PBRM1 GENE; PIK3CA GENE; PRIORITY JOURNAL; PROMOTER REGION; PTEN GENE; REVIEW; RHOA GENE; RNF43 GENE; ROS1 GENE; SETD2 GENE; SIGNAL TRANSDUCTION; SIRT1 GENE; SLC1A2 GENE; SLC34A2 GENE; SMARCA1 GENE; SMARCC1 GENE; STOMACH CANCER; TUMOR SUPPRESSOR GENE; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY; STOMACH TUMOR;

EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; STOMACH NEOPLASMS;

EID: 84964735394     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw040     Document Type: Review

References (87)

1. Global Burden of Disease Cancer CollabrationFitzmaurice C, Dicker D et al. The Global Burden of Cancer 2013. JAMA Oncol 2015; 1: 505-527.
2. Bray F, Ferlay J, Laversanne M et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X, and the global status of cancer registration. Int J Cancer 2015; 137: 2060-2071.
3. Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? What are the suggestions? Crit Rev Oncol Hematol 2001; 40: 77-94.
4. Arnold M, Karim-Kos HE, Coebergh JW et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 2015; 51: 1164-1187.
5. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-1131.
6. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789.
7. Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol 2008; 14: 1149-1155.
8. Dicken BJ, Bigam DL, Cass C et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241: 27-39.
9. Shen L, Xu JM, Feng FY et al. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a phase III, multi-center, randomized controlled trial, Chinese subreport]. Zhonghua Zhong Liu Za Zhi 2013; 35: 295-300.
10. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697.
11. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209.
12. Shah MA, Khanin R, Tang L et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011; 17: 2693-2701.
13. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.
14. Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
15. Chen K, Yang D, Li X et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci USA 2015; 112: 1107-1112.
16. Zang ZJ, Cutcutache I, Poon SL et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012; 44: 570-574.
17. Wang K, Kan J, Yuen ST et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011; 43: 1219-1223.
18. Je EM, Lee SH, Yoo NJ, Lee SH. Mutational and expressional analysis of MLL genes in gastric and colorectal cancers with microsatellite instability. Neoplasma 2013; 60: 188-195.
19. Majewski IJ, Kluijt I, Cats A et al. An alpha-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol 2013; 229: 621-629.
20. Wang K, Yuen ST, Xu J et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014; 46: 573-582.
21. Kakiuchi M, Nishizawa T, Ueda H et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 2014; 46: 583-587.
22. Holbrook JD, Parker JS, Gallagher KT et al. Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J Transl Med 2011; 9: 119.
23. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-16.
24. Sudarsanam P, Winston F. The Swi/Snf family nucleosome-remodeling complexes and transcriptional control. Trends Genet 2000; 16: 345-351.
25. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 1-24.
26. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192-1205.
27. Madan B, Ke Z, Harmston N et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene 2015.
28. Jaiswal BS, Kljavin NM, Stawiski EW et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013; 23: 603-617.
29. Willems L, Tamburini J, Chapuis N et al. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012; 14: 129-138.
30. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
31. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
32. Janku F, Hong DS, Fu S et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014; 6: 377-387.
33. Hudler P. Genetic aspects of gastric cancer instability. Sci World J 2012; 2012: 761909.
34. Baudis M. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer 2007; 7: 226.
35. NCI and NCBI-s SKY/M-FISH and CGH Database. http://www.ncbi.nlm.nih.gov/sky/ skyweb.cgi. 2001.
36. Mitelman F JBaMFE. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman (11 November 2015, date last accessed). 2015.
37. Kim KM, Kwon MS, Hong SJ et al. Genetic classification of intestinal-type and diffuse-type gastric cancers based on chromosomal loss and microsatellite instability. Virchows Arch 2003; 443: 491-500.
38. Wu MS, Chang MC, Huang SP et al. Correlation of histologic subtypes and replication error phenotype with comparative genomic hybridization in gastric cancer. Genes Chromosomes Cancer 2001; 30: 80-86.
39. Weiss MM, Kuipers EJ, Postma C et al. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol 2004; 26: 307-317.
40. Chia NY, Deng N, Das K et al. Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. Gut 2015; 64: 707-719.
41. Deng N, Goh LK, Wang H et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and cooccurrence among distinct therapeutic targets. Gut 2012; 61: 673-684.
42. Garber K. MET inhibitors start on road to recovery. Nat Rev Drug Discov 2014; 13: 563-565.
43. Piccart-Gebhart MHA, Baselga J et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L), or their combination (T + L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). In Presented at 2014 ASCO Annual Meeting Press Briefing, Chicago, IL, 1 June 2014. Abstract LBA4.
44. Satoh T, Xu RH, Chung HC et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study. J Clin Oncol 2014; 32: 2039-2049.
45. Hecht JR, Bang YJ, Qin SK et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/ LOGiC-a randomized phase III trial. J Clin Oncol 2016; 34: 443-451.
46. Kim J, Fox C, Peng S et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest 2014; 124: 5145-5158.
47. Hong SJ, Jeon EJ, Oh JH et al. The gene-reduction effect of chromosomal losses detected in gastric cancers. BMC Gastroenterol 2010; 10: 138.
48. Gazvoda B, Juvan R, Zupanic-Pajnic I et al. Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA. Eur J Gastroenterol Hepatol 2007; 19: 1082-1089.
49. Tao J, Deng NT, Ramnarayanan K et al. CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med 2011; 3: 77ra30.
50. Lee J, Lee SE, Kang SY et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 2013; 119: 1627-1635.
51. Yao F, Kausalya JP, Sia YY et al. Recurrent fusion genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial integrity. Cell Rep 2015; 12: 272-285.
52. Buffart TE, Louw M, van Grieken NC et al. Gastric cancers of Western European and African patients show different patterns of genomic instability. BMC Med Genomics 2011; 4: 7.
53. Rossi E, Klersy C, Manca R et al. Correlation between genomic alterations assessed by array comparative genomic hybridization, prognostically informative histologic subtype, stage, and patient survival in gastric cancer. Hum Pathol 2011; 42: 1937-1945.
54. Lin SJ, Gagnon-Bartsch JA, Tan IB et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 2015; 64: 1721-1731.
55. Vecchi M, Nuciforo P, Romagnoli S et al. Gene expression analysis of early and advanced gastric cancers. Oncogene 2007; 26: 4284-4294.
56. Nam S, Lee J, Goh SH et al. Differential gene expression pattern in early gastric cancer by an integrative systematic approach. Int J Oncol 2012; 41: 1675-1682.
57. Chang HR, Nam S, Kook MC et al. HNF4alpha is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 2016; 65: 19-32.
58. Kim YH, Liang H, Liu X et al. AMPKalpha modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res 2012; 72: 2512-2521.
59. Yamada Y, Arao T, Gotoda T et al. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci 2008; 99: 2193-2199.
60. Cho JY, Lim JY, Cheong JH et al. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 2011; 17: 1850-1857.
61. Takeno A, Takemasa I, Seno S et al. Gene expression profile prospectively predicts peritoneal relapse after curative surgery of gastric cancer. Ann Surg Oncol 2010; 17: 1033-1042.
62. Lee J, Sohn I, Do IG et al. Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS ONE 2014; 9: e90133.
63. Tan IB, Ivanova T, Lim KH et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011; 141: 476-485, 485 e471-411.
64. Lei Z, Tan IB, Das K et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 2013; 145: 554-565.
65. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350-1356.
66. Cristescu R, Lee J, Nebozhyn M et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015; 21: 449-456.
67. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
68. Fleisher AS, Esteller M, Wang S et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59: 1090-1095.
69. Leung SY, Yuen ST, Chung LP et al. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 1999; 59: 159-164.
70. Ottini L, Falchetti M, Lupi R et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 2006; 17(Suppl 7): vii97-vii102.
71. Falchetti M, Saieva C, Lupi R et al. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol 2008; 39: 925-932.
72. Fang WL, Chang SC, Lan YT et al. Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery. World J Surg 2012; 36: 2131-2138.
73. An C, Choi IS, Yao JC et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11: 656-663.
74. Zazula M, Ferreira AM, Czopek JP et al. CDH1 gene promoter hypermethylation in gastric cancer: relationship to Goseki grading, microsatellite instability status, and EBV invasion. Diagn Mol Pathol 2006; 15: 24-29.
75. Oshimo Y, Oue N, Mitani Y et al. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 2004; 71: 137-143.
76. Yoda Y, Takeshima H, Niwa T et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer 2015; 18: 65-76.
77. Toyota M, Ahuja N, Suzuki H et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59: 5438-5442.
78. Zouridis H, Deng N, Ivanova T et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med 2012; 4: 156ra140.
79. Kim JG, Takeshima H, Niwa T et al. Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers. Cancer Lett 2013; 330: 33-40.
80. Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
81. Maekita T, Nakazawa K, Mihara M et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12: 989-995.
82. Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res 2012; 72: 3445-3450.
83. Zhang L, Zhong K, Dai Y, Zhou H. Genome-wide analysis of histone H3 lysine 27 trimethylation by ChIP-chip in gastric cancer patients. J Gastroenterol 2009; 44: 305-312.
84. Muratani M, Deng N, Ooi WF et al. Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. Nat Commun 2014; 5: 4361.
85. Hecht JR, Bang YJ, Qin SK et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/ LOGiC- A Randomized Phase III Trial. J Clin Oncol 2016; 34: 443-451.
86. Sunakawa Y, Stremitzer S, Cao S et al. Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Ann Oncol 2015; 26: 332-339.
87. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-1437.